Starpharma (ASX:SPL) share price jumps 15% after COVID-19 nasal spray update

The Starpharma Holdings Limited (ASX:SPL) share price is surging higher on Thursday after an update on its COVID-19 nasal spray…

| More on:
Group of young friends wearing facemasks dining out and raising glasses in a toast

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price has surged higher on Thursday following the release of a big announcement.

At the time of writing, the biopharmaceutical company's shares are up 15% to $1.50.

What did Starpharma announce?

This morning Starpharma announced that significant commercial and regulatory progress has been made for its Viraleze nasal spray.

According to the release, the European Union (EU) regulatory dossier is now more than 90% complete, which means Viraleze is on track to be registered and ready for market in the first quarter of calendar year 2021.

This is earlier than the company was expecting and had previously announced.

What is Viraleze?

Viraleze will be marketed as an antiviral nasal spray for SARS-CoV-2, which is the coronavirus that causes COVID-19.

It will also be marketed as an antiviral nasal spray for other important respiratory viruses such as influenza and RSV.

Management believes Viraleze will "form part of a range of preventative measures such as masks and other PPE, and is complimentary (sic) to COVID-19 vaccines to further reduce risk of infection."

What's next?

Starpharma has revealed that its pre-launch commercialisation activities for Viraleze are well advanced with input from Boston Consulting Group.

Activities are initially focusing on direct to consumer and business-to-business channels to facilitate the most rapid entry to market. In addition to this, the company is continuing partnering discussions.

Europe will be the first geographic region for the Viraleze launch. After which, Starpharma plans to leverage its European registration to roll-out the product into other markets including Australia as quickly as possible.

As part of the go-to-market planning, qualitative and quantitative consumer research was undertaken in Europe during November.

The research from ~1,500 consumers confirmed that the product proposition for Viraleze is highly appealing. It also found that consumers would use the product in a wide range of settings. This includes in crowded areas such as shopping centres, elevators, workplaces, and public transport.

Starpharma's CEO, Dr Jackie Fairley, commented: "We know from the positive market research that VIRALEZE has the ability to restore confidence and encourage people to resume everyday professional and recreational activities. Our market research also shows that the compelling features and convenience of VIRALEZE are highly appealing to consumers."

"The distribution challenges of COVID-19 vaccines are well documented including the timing of wide-spread availability and adoption. Even after a vaccine becomes widely available, social distancing, PPE and other measures will continue to be important and VIRALEZE complements other prevention strategies, including vaccines. In November, the World Health Organisation stated that someone died every 17 seconds from COVID-19 in Europe. It is with the greatest urgency that Starpharma is working to make this product ready for market as quickly as possible in 1Q CY2021," she added.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A older man and younger man rest, exhausted but happy after a good boxing session.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors enjoyed an optimistic start to the week's trading today.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Share Gainers

Why Dateline, DigiCo, Liontown, and Pilbara Minerals shares are racing higher today

These shares are starting the week with a bang. But why?

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing end to the trading week this Friday.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Gainers

3 ASX 200 stocks racing ahead of the benchmark this week

Investors sent these three ASX 200 stocks rocketing over the week. But why?

Read more »

A woman looks quizzical while looking at a dollar sign in the air.
Share Gainers

After 50% or more share price growth, should you sell these ASX 200 winners?

These stocks wowed investors with their magnificent share price growth in FY25. What now?

Read more »

Smiling couple sitting on a couch with laptops fist pump each other.
Share Gainers

Why Block, Iress, Nick Scali, and Westgold shares are storming higher today

These shares are ending the week with a bang. But why?

Read more »

Miner looking at his notes.
Industrials Shares

Forget BHP, this little known gem is roaring 30% in FY 2026

This little-known services company is quietly capitalising on mining and infrastructure activity across nine countries, and investors are starting to…

Read more »

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a timid session for investors this Thursday.

Read more »